SAN DIEGO – Allele-specific KRAS inhibitors are “the most exciting change coming down the pike for treating KRAS-mutant tumors in the near future,” Ferdinandos Skoulidis said at the sixth joint conference by the American Association for Cancer Research and the International Association for the Study of Lung Cancer meeting.